Human African trypanosomiasis: potential therapeutic benefits of an alternative suramin and melarsoprol regimen (Q44209129)

30 November 2017

Human African trypanosomiasis: potential therapeutic benefits of an alternative suramin and melarsoprol regimen (English)

1 reference

30 November 2017

0 references

0 references

African trypanosomiasis

0 references

1 reference

Jean Rodgers

2

0 references

author name string

Frank W Jennings

1

1 reference

30 November 2017

Barbara Bradley

3

1 reference

30 November 2017

George Gettinby

4

1 reference

30 November 2017

Peter G E Kennedy

5

1 reference

30 November 2017

Max Murray

6

1 reference

30 November 2017

1 December 2002

1 reference

Parasitology International

30 November 2017

1 reference

30 November 2017

51

1 reference

30 November 2017

4

1 reference

30 November 2017

381-388

1 reference

Immunopathology in central nervous system human African trypanosomiasis

30 November 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5769%2802%2900044-2

7 January 2021

African trypanosomiasis and drug-induced encephalopathy: risk factors and pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5769%2802%2900044-2

7 January 2021

The lesions produced in the central nervous system by certain organic arsenical compounds.

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5769%2802%2900044-2

7 January 2021

Immune complexes in serum and in cerebrospinal fluid in African trypanosomiasis. Correlation with polyclonal B cell activation and with intracerebral immunoglobulin synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5769%2802%2900044-2

7 January 2021

Immunopathological and chemotherapeutic studies in experimental trypanosomiasis with special reference to the heart and brain

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5769%2802%2900044-2

7 January 2021

Mel B in the treatment of human trypanosomiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5769%2802%2900044-2

7 January 2021

Efficacy of new, concise schedule for melarsoprol in treatment of sleeping sickness caused by Trypanosoma brucei gambiense: a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5769%2802%2900044-2

7 January 2021

The treatment of human African trypanosomiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5769%2802%2900044-2

7 January 2021

Successful treatment of experimental murine Trypanosoma brucei infection with topical melarsoprol gel.

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5769%2802%2900044-2

7 January 2021

Topical melarsoprol for trypanosomiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5769%2802%2900044-2

7 January 2021

Topical chemotherapy for experimental murine African CNS-trypanosomiasis: the successful use of the arsenical, melarsoprol, combined with the 5-nitroimidazoles, fexinidazole or MK-436.

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5769%2802%2900044-2

7 January 2021

Topical chemotherapy for experimental African trypanosomiasis with cerebral involvement: the use of melarsoprol combined with the 5-nitroimidazole, megazol

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5769%2802%2900044-2

7 January 2021

Combination chemotherapy of CNS trypanosomiasis

1 reference

https://api.crossref.org/works/10.1016%2FS1383-5769%2802%2900044-2

7 January 2021

10.1016/S1383-5769(02)00044-2

Identifiers

DOI

1 reference

30 November 2017

1 reference